MorphoSys is a late-stage, biopharmaceutical company devoted to the development of innovative and differentiated therapies for patients suffering from serious diseases. Based on its technological leadership in generating antibodies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 29 are currently in clinical development. This broad pipeline spans MorphoSys's two business segments: Proprietary Development, in which MorphoSys invests in product candidates for its own account, and Partnered Discovery, in which product candidates are developed exclusively for a variety of Pharma and Biotech partners. Tremfya® (guselkumab), marketed by Janssen, became the first therapeutic antibody based on MorphoSys's proprietary technology to receive marketing approval for the treatment of moderate to severe plaque psoriasis in the United States, the European Union, Canada, Japan and a number of other countries worldwide. Headquartered in Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., had 322 employees on September 30, 2018. MorphoSys US Inc. started operations in July 2018 with the primary focus to establish a strong U.S. footprint for MorphoSys and to build the Company’s capabilities in preparation for the planned U.S. commercialization of MOR208. MorphoSys is listed on the Frankfurt Stock Exchange and on the U.S. stock exchange Nasdaq under the symbol MOR. For regular updates about MorphoSys, visit www.morphosys.com.